Developer docs
API playgroundTry for free, no card

Search company profiles

Ceribell

Full company profile

uuid000029j

Namestring
Ceribell
Legal namestring
Ceribell, Inc.
Websiteurl
ceribell.com
Company typeenum
Public
Founded yearint
2014
Descriptiontext

Ceribell, Inc. (NASDAQ: CBLL) is a medical technology company founded in 2014 and headquartered in Sunnyvale, California, that has built a point-of-care EEG platform for rapid bedside brain monitoring in non-specialist settings such as intensive care units, emergency departments, and neonatal/pediatric ICUs. The platform pairs a portable recorder with a disposable single-use headband and a cloud-based portal, allowing any trained clinician to initiate EEG monitoring within minutes without requiring a dedicated EEG technologist. Layered on the hardware is the proprietary Clarity AI algorithm — an FDA-cleared machine-learning model that interprets EEG waveforms in near real time, computes a rolling seizure-burden estimate, and issues color-coded bedside alerts. The company also offers the Brain Stethoscope sonification feature, a FedRAMP High-authorized EEG Portal for remote neurologist review, and a neonatal headband variant for preterm and newborn patients.

Ceribell operates a hybrid revenue model combining one-time hardware placement (recorders deployed at hospitals) with per-patient recurring consumable revenue from disposable headbands and a software/AI subscription for Clarity and the EEG Portal. Pricing is quote-based under multi-year contracts, and hospitals can leverage CMS New Technology Add-on Payments (NTAP) of up to $913.90 per eligible patient as well as existing CPT codes to support procedure-level reimbursement. The company is installed at 600+ U.S. hospitals (~11% of U.S. hospitals) and has expanded its sales force from approximately 35 to 55 territories; a recent FedRAMP High authorization opens the 170-hospital U.S. Veterans Affairs system. Following a $53 million Series C in 2021, Ceribell completed its NASDAQ IPO in October 2024, raising approximately $180 million at a $578 million valuation.

FY2025 revenue reached $89.1 million (36% YoY growth) on approximately 85% gross margins, with Q1 2026 revenue of $26.5 million (29% YoY). The company is expanding its clinical indications — including FDA Breakthrough Device Designation for Large Vessel Occlusion stroke detection (January 2026), FDA clearance for AI-powered delirium monitoring (December 2025), and FDA 510(k) clearance of the Clarity algorithm for neonates (November 2025) — while pursuing active ITC patent litigation against incumbent EEG vendor Natus.

Short descriptiontext

Ceribell (NASDAQ: CBLL) is a publicly traded medical technology company that sells a portable, cloud-connected EEG platform with the FDA-cleared Clarity AI algorithm for rapid bedside seizure and brain monitoring in U.S. hospitals, ICUs, emergency departments, and neonatal/pediatric care settings.

Operating statusenum
Ipo
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersSunnyvale, United States
HQ citystring
Sunnyvale
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
point-of-care EEG, AI seizure detection, brain monitoring devices, neurology medical devices, EEG headbands
Industry5 codes
PRIMARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLALAGAC
Neurology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYHLALAFAJ
Neurology RPM (epilepsy, Parkinson’s, MS monitoring)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLAKAIAB
Epilepsy & Seizure Disorders
SECONDARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
NAICS code2 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Navigational, Measuring, Electromedical, and Control Instruments Manufacturing33451
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
Product category
Neurology Medical Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Hardware Sales
TypeHardware Sales
Description

Revenue from sale of the Ceribell EEG recorder and disposable headbands (single-use electrodes). The recorder is typically deployed with the customer, and headbands generate recurring consumable revenue per patient monitoring session.

Cost components6 values
Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Infrastructure, Operations
Pricing details1 tier
1Hybrid hardware + subscription pricing (quote-based)
ModelHybridBilling cadenceMulti-year contract
Notes

Not publicly disclosed; pricing is quote-based. Customers pay for the EEG recorder hardware plus disposable single-use headbands per patient monitored, combined with a recurring software subscription for the Clarity AI algorithm and cloud portal. Hospitals can leverage CMS NTAP (New Technology Add-on Payments) of up to $913.90 per eligible patient and existing CPT codes for EEG procedures to support ROI.

GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Clarity
Description

Ceribell's proprietary AI algorithm that interprets EEG waveforms, detects seizures, and provides real-time bedside alerts for status epilepticus across all age groups (preterm neonates through adults).

ceribell.com
+2 more records
Core offering1 text field

Ceribell develops and sells a point-of-care EEG brain monitoring platform that combines a portable handheld recorder, disposable single-use headbands, and the FDA-cleared Clarity AI algorithm to enable non-specialist clinical staff to perform bedside brain monitoring and seizure detection within minutes. The system is paired with a FedRAMP High-authorized cloud-based EEG Portal for remote neurologist review and is deployed across ICU, emergency department, neurology, pediatric ICU, and neonatal ICU settings in U.S. hospitals.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Ceribell offers a platform-plus-modules architecture centered on a single unified point-of-care EEG hardware system. The core is the Ceribell Point-of-Care EEG System — a portable, wearable EEG hardware platform (recorder + disposable headband) that any trained provider can deploy at the bedside in minutes. Layered on this hardware are three software/service modules: the Clarity® AI Algorithm (cloud-based seizure-detection and seizure-burden AI that triggers bedside alerts), the Ceribell EEG Portal (a FedRAMP High-authorized cloud platform for remote review, reporting, and notifications), and the Brain Stethoscope® sonification feature. The Neonatal Headband is a specialized hardware accessory that pairs with the same core system and Clarity algorithm to extend coverage to preterm and newborn patients.

Product and service5 records
1Ceribell Point-of-Care EEG System
CategoryCore Product (Medical Device Hardware)
Description

A portable, wearable EEG hardware platform combining a disposable headband with a handheld recorder that enables any trained healthcare provider to initiate brain monitoring at the bedside in minutes without an EEG technician. Designed for ICU, ED, neurology, pediatric ICU, and neonatal ICU use; FDA 510(k)-cleared (K223504) for indicating suspected seizure activity.

2Clarity AI Algorithm
CategoryAI Software Module
Description

Proprietary cloud-based machine-learning algorithm that continuously interprets the patient's EEG waveforms every 10 seconds to compute a 5-minute seizure burden estimate and trigger bedside alerts for suspected status epilepticus and continuous seizures. FDA-cleared for adults, pediatric patients (2025), and neonates (2025). Validated in 35+ publications with 95% sensitivity and 97% specificity at ≥90% seizure burden.

3Ceribell EEG Portal
CategoryCloud Platform / Software
Description

Intuitive, FedRAMP High-authorized cloud-based management platform for remote, real-time review of Ceribell EEG recordings with pre-annotated Clarity AI insights, custom notifications, smart EEG reports, and an embedded expert-annotated EEG Reference Library. Supports desktop and mobile review for neurologists, ICU, and ED teams.

4Ceribell Neonatal Headband (EEG Headcap)
CategorySpecialized Hardware Accessory
Description

Disposable silicone-barrier EEG headcap designed for preterm and newborn infants (head circumference 26–46.5 cm) with protective skin barrier, easy fontanelle access for head ultrasounds, and stretchable fabric. Pairs with the Ceribell Point-of-Care EEG System and Clarity algorithm (FDA-cleared for neonates).

5Brain Stethoscope
CategoryCompanion Sonification Tool
Description

Sonification feature used with the Ceribell EEG system that converts EEG patterns into audible sounds, evaluated in the DECIDE trial where ED physicians identified seizures with 100% sensitivity and 92% specificity using Brain Stethoscope combined with Ceribell EEG.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
1iCE Neurosciences
TypeEmerging player
Description

Emerging continuous EEG monitoring platform focused on critical care. Direct overlap with Ceribell's ICU/CCU use case but with a smaller commercial footprint; relevant as a niche next-generation competitor.

TypeDirect peer
Description

The dominant legacy neurodiagnostic equipment vendor, with conventional EEG systems, long-term monitoring, and ICU EEG offerings. Directly comparable to Ceribell across Ceribell's core U.S. EEG customer base, and is the explicit defendant in Ceribell's ongoing ITC patent litigation.

TypeDirect peer
Description

EEG-based diagnostic and therapeutic device company with focus on neurological assessment and brain injury. Operates in the same EEG/neuromonitoring category as Ceribell and is a relevant emerging competitor in the U.S. neurodiagnostic market.

TypeDirect peer
Description

Privately held neurodiagnostic and sleep-diagnostic equipment manufacturer selling EEG, EMG, and IOM systems into U.S. hospitals. Directly comparable as a long-standing specialty EEG competitor to Ceribell's point-of-care platform.

TypeDirect peer
Description

Australia-based neurodiagnostic and sleep-diagnostic equipment maker (Neuvo, E-Series, Profusion) used in hospitals and research settings. Comparable as a specialty EEG and sleep-monitoring hardware/software vendor targeting similar hospital customers.

TypeDirect peer
Description

EEG hardware and cloud review platform (Stratus EEG, Trackit) used in ICU, EMU, and ambulatory settings. Closely comparable to Ceribell's hardware-plus-portal model, particularly for ambulatory and EMU EEG, and competes for the same neurology and ICU budgets.

TypeBroad incumbent
Description

Large patient-monitoring incumbent with hospital-wide bedside monitoring, including EEG-adjacent brain-monitoring products (e.g., SedLine). Sells into the same ICU customer base as Ceribell and represents a broader, more diversified incumbent in the hospital monitoring category.

TypeBroad incumbent
Description

Global medtech incumbent with a large hospital patient-monitoring portfolio and a dedicated neurodiagnostic EEG line. Competes for the same hospital EEG budgets as part of a much broader monitoring, imaging, and clinical informatics portfolio.

TypeBroad incumbent
Description

Large neurology-focused medtech incumbent with brain and spinal therapies. While not a direct EEG hardware peer, it occupies the broader neurology hospital ecosystem in which Ceribell sells and could plausibly enter bedside brain monitoring via M&A or internal development.

TypeEmerging player
Description

Emerging EEG and digital biomarker platform with cloud-based analytics, primarily used in clinical trials and CNS drug development. Partially comparable to Ceribell's EEG Portal/Clarity platform for cloud-based EEG analysis, with a different end-customer focus (pharma/biotech).

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles16 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance7 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ceribell

Neurology Medical Devicesceribell.com

Ceribell (NASDAQ: CBLL) is a publicly traded medical technology company that sells a portable, cloud-connected EEG platform with the FDA-cleared Clarity AI algorithm for rapid bedside seizure and brain monitoring in U.S. hospitals, ICUs, emergency departments, and neonatal/pediatric care settings.

What Ceribell does

Ceribell, Inc. (NASDAQ: CBLL) is a medical technology company founded in 2014 and headquartered in Sunnyvale, California, that has built a point-of-care EEG platform for rapid bedside brain monitoring in non-specialist settings such as intensive care units, emergency departments, and neonatal/pediatric ICUs. The platform pairs a portable recorder with a disposable single-use headband and a cloud-based portal, allowing any trained clinician to initiate EEG monitoring within minutes without requiring a dedicated EEG technologist. Layered on the hardware is the proprietary Clarity AI algorithm — an FDA-cleared machine-learning model that interprets EEG waveforms in near real time, computes a rolling seizure-burden estimate, and issues color-coded bedside alerts. The company also offers the Brain Stethoscope sonification feature, a FedRAMP High-authorized EEG Portal for remote neurologist review, and a neonatal headband variant for preterm and newborn patients.

Ceribell operates a hybrid revenue model combining one-time hardware placement (recorders deployed at hospitals) with per-patient recurring consumable revenue from disposable headbands and a software/AI subscription for Clarity and the EEG Portal. Pricing is quote-based under multi-year contracts, and hospitals can leverage CMS New Technology Add-on Payments (NTAP) of up to $913.90 per eligible patient as well as existing CPT codes to support procedure-level reimbursement. The company is installed at 600+ U.S. hospitals (~11% of U.S. hospitals) and has expanded its sales force from approximately 35 to 55 territories; a recent FedRAMP High authorization opens the 170-hospital U.S. Veterans Affairs system. Following a $53 million Series C in 2021, Ceribell completed its NASDAQ IPO in October 2024, raising approximately $180 million at a $578 million valuation.

FY2025 revenue reached $89.1 million (36% YoY growth) on approximately 85% gross margins, with Q1 2026 revenue of $26.5 million (29% YoY). The company is expanding its clinical indications — including FDA Breakthrough Device Designation for Large Vessel Occlusion stroke detection (January 2026), FDA clearance for AI-powered delirium monitoring (December 2025), and FDA 510(k) clearance of the Clarity algorithm for neonates (November 2025) — while pursuing active ITC patent litigation against incumbent EEG vendor Natus.

Ceribell firmographics

Firmographics
Name
Ceribell
Legal name
Ceribell, Inc.
Website
https://ceribell.com
Company type
Public
Founded year
2014
Operating status
Ipo
Headcount range
251–500 employees
Short description
Ceribell (NASDAQ: CBLL) is a publicly traded medical technology company that sells a portable, cloud-connected EEG platform with the FDA-cleared Clarity AI algorithm for rapid bedside seizure and brain monitoring in U.S. hospitals, ICUs, emergency departments, and neonatal/pediatric care settings.
Ownership category
akta.pro rank

Ceribell industry classification

Industry
Product category
Neurology Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHACAE
Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLALAGAC
Neurology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYHLALAFAJ
Neurology RPM (epilepsy, Parkinson’s, MS monitoring)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
SECONDARYHLAKAIAB
Epilepsy & Seizure Disorders
SECONDARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring

Keywords

  • Point-of-care EEG
  • AI seizure detection
  • Brain monitoring devices
  • Neurology medical devices
  • EEG headbands

Where Ceribell is headquartered

Location

Headquarters

HQ city
Sunnyvale
HQ country
United States
HQ region
North America

Markets served

Ceribell business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Personnel, Marketing or Sales, Technology or R&D, Infrastructure, Operations

Revenue model

  1. Hardware Sales: Revenue from sale of the Ceribell EEG recorder and disposable headbands (single-use electrodes). The recorder is typically deployed with the customer, and headbands generate recurring consumable revenue per patient monitoring session.

Pricing tiers

ModelBillingPrice
HybridMulti-year contractHybrid hardware + subscription pricing (quote-based)

Go-to-market motion1 record

Ceribell product offering

Product offering

Core offering

Ceribell develops and sells a point-of-care EEG brain monitoring platform that combines a portable handheld recorder, disposable single-use headbands, and the FDA-cleared Clarity AI algorithm to enable non-specialist clinical staff to perform bedside brain monitoring and seizure detection within minutes. The system is paired with a FedRAMP High-authorized cloud-based EEG Portal for remote neurologist review and is deployed across ICU, emergency department, neurology, pediatric ICU, and neonatal ICU settings in U.S. hospitals.

Product overview

Ceribell offers a platform-plus-modules architecture centered on a single unified point-of-care EEG hardware system. The core is the Ceribell Point-of-Care EEG System — a portable, wearable EEG hardware platform (recorder + disposable headband) that any trained provider can deploy at the bedside in minutes. Layered on this hardware are three software/service modules: the Clarity® AI Algorithm (cloud-based seizure-detection and seizure-burden AI that triggers bedside alerts), the Ceribell EEG Portal (a FedRAMP High-authorized cloud platform for remote review, reporting, and notifications), and the Brain Stethoscope® sonification feature. The Neonatal Headband is a specialized hardware accessory that pairs with the same core system and Clarity algorithm to extend coverage to preterm and newborn patients.

Differentiator

Problem solved

Functional benefit

Brands

  • Clarity: Ceribell's proprietary AI algorithm that interprets EEG waveforms, detects seizures, and provides real-time bedside alerts for status epilepticus across all age groups (preterm neonates through adults).
  • Ceribell System (Ceribell Point-of-Care EEG)
  • Ceribell EEG Portal

Products and services

  • Ceribell Point-of-Care EEG System A portable, wearable EEG hardware platform combining a disposable headband with a handheld recorder that enables any trained healthcare provider to initiate brain monitoring at the bedside in minutes without an EEG technician. Designed for ICU, ED, neurology, pediatric ICU, and neonatal ICU use; FDA 510(k)-cleared (K223504) for indicating suspected seizure activity.
  • Clarity AI Algorithm Proprietary cloud-based machine-learning algorithm that continuously interprets the patient's EEG waveforms every 10 seconds to compute a 5-minute seizure burden estimate and trigger bedside alerts for suspected status epilepticus and continuous seizures. FDA-cleared for adults, pediatric patients (2025), and neonates (2025). Validated in 35+ publications with 95% sensitivity and 97% specificity at ≥90% seizure burden.
  • Ceribell EEG Portal Intuitive, FedRAMP High-authorized cloud-based management platform for remote, real-time review of Ceribell EEG recordings with pre-annotated Clarity AI insights, custom notifications, smart EEG reports, and an embedded expert-annotated EEG Reference Library. Supports desktop and mobile review for neurologists, ICU, and ED teams.
  • Ceribell Neonatal Headband (EEG Headcap) Disposable silicone-barrier EEG headcap designed for preterm and newborn infants (head circumference 26–46.5 cm) with protective skin barrier, easy fontanelle access for head ultrasounds, and stretchable fabric. Pairs with the Ceribell Point-of-Care EEG System and Clarity algorithm (FDA-cleared for neonates).
  • Brain Stethoscope Sonification feature used with the Ceribell EEG system that converts EEG patterns into audible sounds, evaluated in the DECIDE trial where ED physicians identified seizures with 100% sensitivity and 92% specificity using Brain Stethoscope combined with Ceribell EEG.

Companies that use Ceribell

Customer profile

Ideal customer profiles2 records

Ceribell technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability1 record

Feature6 records

Ceribell partnerships and signals

Strategic signal

Recent moves7 records

Expansion highlights7 records

Ceribell competitors and assessment

Company assessment

Emerging players

  • iCE Neurosciences: Emerging continuous EEG monitoring platform focused on critical care. Direct overlap with Ceribell's ICU/CCU use case but with a smaller commercial footprint; relevant as a niche next-generation competitor.
  • Cumulus Neuroscience: Emerging EEG and digital biomarker platform with cloud-based analytics, primarily used in clinical trials and CNS drug development. Partially comparable to Ceribell's EEG Portal/Clarity platform for cloud-based EEG analysis, with a different end-customer focus (pharma/biotech).

Direct peers

  • Natus Medical: The dominant legacy neurodiagnostic equipment vendor, with conventional EEG systems, long-term monitoring, and ICU EEG offerings. Directly comparable to Ceribell across Ceribell's core U.S. EEG customer base, and is the explicit defendant in Ceribell's ongoing ITC patent litigation.
  • Wave Neuroscience: EEG-based diagnostic and therapeutic device company with focus on neurological assessment and brain injury. Operates in the same EEG/neuromonitoring category as Ceribell and is a relevant emerging competitor in the U.S. neurodiagnostic market.
  • Cadwell Industries: Privately held neurodiagnostic and sleep-diagnostic equipment manufacturer selling EEG, EMG, and IOM systems into U.S. hospitals. Directly comparable as a long-standing specialty EEG competitor to Ceribell's point-of-care platform.
  • Compumedics: Australia-based neurodiagnostic and sleep-diagnostic equipment maker (Neuvo, E-Series, Profusion) used in hospitals and research settings. Comparable as a specialty EEG and sleep-monitoring hardware/software vendor targeting similar hospital customers.
  • Lifelines Neuro (Stratus EEG): EEG hardware and cloud review platform (Stratus EEG, Trackit) used in ICU, EMU, and ambulatory settings. Closely comparable to Ceribell's hardware-plus-portal model, particularly for ambulatory and EMU EEG, and competes for the same neurology and ICU budgets.

Broad incumbents

  • Masimo: Large patient-monitoring incumbent with hospital-wide bedside monitoring, including EEG-adjacent brain-monitoring products (e.g., SedLine). Sells into the same ICU customer base as Ceribell and represents a broader, more diversified incumbent in the hospital monitoring category.
  • Philips: Global medtech incumbent with a large hospital patient-monitoring portfolio and a dedicated neurodiagnostic EEG line. Competes for the same hospital EEG budgets as part of a much broader monitoring, imaging, and clinical informatics portfolio.
  • Medtronic: Large neurology-focused medtech incumbent with brain and spinal therapies. While not a direct EEG hardware peer, it occupies the broader neurology hospital ecosystem in which Ceribell sells and could plausibly enter bedside brain monitoring via M&A or internal development.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Ceribell social profiles

Digital presence

Ceribell compliance and trust

Trust signal

Compliance7 records

Ceribell financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ceribell leadership team

Management profile

Number of profiles

Profiles16 records

Ceribell funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ceribell M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ceribell

What does Ceribell do?

Ceribell develops and sells a point-of-care EEG brain monitoring platform that combines a portable handheld recorder, disposable single-use headbands, and the FDA-cleared Clarity AI algorithm to enable non-specialist clinical staff to perform bedside brain monitoring and seizure detection within minutes. The system is paired with a FedRAMP High-authorized cloud-based EEG Portal for remote neurologist review and is deployed across ICU, emergency department, neurology, pediatric ICU, and neonatal ICU settings in U.S. hospitals.

Is Ceribell a public or private company?

Ceribell is a public company. It is classified as public and is currently ipo.

When was Ceribell founded?

Ceribell was founded in 2014. It employs 251 to 500 people.

Where is Ceribell based?

Ceribell is headquartered in Sunnyvale, United States, in the North America region.

How does Ceribell make money?

One revenue line is on record: hardware Sales.

Who are Ceribell's main competitors?

Emerging players on record are iCE Neurosciences and Cumulus Neuroscience. Direct peers are Natus Medical, Wave Neuroscience, Cadwell Industries, Compumedics and Lifelines Neuro (Stratus EEG). Broad incumbents are Masimo, Philips and Medtronic.

Does Ceribell have an API?

No public API is recorded for Ceribell.

What industry is Ceribell in?

Ceribell's product category is Neurology Medical Devices. Its primary akta.pro industry code is HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables), with a secondary code of HLALAGAC, Neurology Telemedicine Platforms. Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooCeribell (CBLL) Stock Looks Stretched Despite New AI Monitoring LaunchCeriBell shares rose 102.6% over the past year, trading at a 9.3x price-to-sales multiple, well above the sector average of 2.6x. The company's FDA-cleared AI delirium monitoring platform has driven hospital adoption and revenue growth, but the valuation leaves little room for disappointment if adoption or pricing power falls short.Investing.comCeriBell at canaccord medtech forum: growth broadens beyond seizuresCeriBell reported 30% revenue growth and 35 new accounts in Q3, serving 747 U.S. hospitals. Management said cash flow breakeven is achievable with $117-118M cash, and delirium detection and the Omni platform could expand beyond seizure monitoring.Simply Wall StIs CeriBell (CBLL) Undervalued Following Its Higher 2026 Guidance And Delirium Launch?CeriBell raised its full-year 2026 revenue outlook to $115-117 million and launched its FDA-cleared delirium monitoring solution with Medicare add-on reimbursement. The stock trades at $27.48, below the $29.57 fair value, with a P/S of 9.8x versus a 7.5x fair ratio. The company's AI-driven neuromonitoring platform may expand its addressable market.TradingViewCeribell Reports 30% Revenue Growth and 90% Gross Margin in Q3 2026Ceribell reported Q3 2026 revenue of $29.3 million, up 30% year over year, with a net loss of $21.4 million and a 90% gross margin. The company raised its 2026 revenue outlook to $115 million to $117 million. It also added 35 net new customers and received FDA 510(k) clearance for EEG analysis.TradingViewCeriBell Q3 2026 Earnings Call Is LiveCeriBell's Q3 2026 earnings call is live, with executives discussing financial results and answering analyst questions. The call may include surprise news, and management commentary on demand, margins, or capital spending can move markets.Investing.comCeribell earnings ahead: Can product expansion accelerate revenue?Ceribell Inc. reports Q3 results after market close, with analysts expecting a $0.34 loss per share, an improvement from Q2's $0.51 loss. The company's addressable market expanded to $3.5 billion after regulatory clearances for pediatric, neonatal, and delirium applications, with Medicare reimbursement for its delirium monitor. Investors watch commercial launch and path to profitability.Simply Wall StDelirium Monitor Launch Could Be A Game Changer For CeriBell Stock (CBLL)CeriBell launched its FDA-cleared delirium monitoring solution on its EEG platform, with CMS granting a New Technology Add-on Payment of up to $2,171 per Medicare case from October 1, 2026. Analysts project revenue growth of 28.8% annually and a turnaround from a $52.5M loss to a $22.9M profit by 2028.stockhouseThis healthtech company improves neurological care with AICeriBell's FDA-approved AI EEG platform diagnoses seizures and delirium in 5 minutes, adopted in over 600 hospitals. Revenue grew 14 quarters from $9.5M to $28.1M, with 92% gross margin. The company guides $114-117M revenue for 2026.Stock TitanCeribell CFO to take part in Canaccord forum Nov. 11Ceribell CFO Scott Blumberg will participate in a fireside chat at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum on November 11, 2026, in New York City. The event will be webcast live and archived on Ceribell's investor relations page.Business & FinancialCeribell To Participate In The Canaccord Genuity Medtech, Diagnostics And Digital Health & Services ForumCeribell will participate in the Canaccord Genuity Medtech, Diagnostics and Digital Health & Services Forum on November 11, 2026. The company's Ceribell System is an FDA-cleared EEG platform for detecting seizures and monitoring delirium in acute-care settings.